Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis

NCT05971602 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT05971602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05971602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis
Lead sponsor
Gates Medical Research Institute
Phase
Phase 2
Overall status
Terminated
Start date
July 26, 2023
Completion date
February 6, 2025
Enrollment
93 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis